Literature DB >> 15124852

Barth syndrome without 3-methylglutaconic aciduria.

M Rahbek Schmidt1, N Birkebaek, I Gonzalez, L Sunde.   

Abstract

UNLABELLED: Barth syndrome involves cardiomyopathy, skeletal myopathy, neutropenia and 3-methylglutaconic (3-mgc) aciduria. 3-mgc aciduria has been observed in almost all reported cases and has served as a diagnostic criterion.
CONCLUSION: A case of confirmed BTHS, but without 3-mgc aciduria, emphasizes the importance of extensive investigations in cases with suspected hereditary cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15124852     DOI: 10.1080/08035250410022837

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

Review 1.  Antenatal manifestations of inborn errors of metabolism: biological diagnosis.

Authors:  Christine Vianey-Saban; Cécile Acquaviva; David Cheillan; Sophie Collardeau-Frachon; Laurent Guibaud; Cécile Pagan; Magali Pettazzoni; Monique Piraud; Antonin Lamazière; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2016-07-08       Impact factor: 4.982

Review 2.  Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review.

Authors:  Ting-Yu Yen; Wuh-Liang Hwu; Yin-Hsiu Chien; Mei-Hwan Wu; Ming-Tai Lin; Lon-Yen Tsao; Wu-Shiun Hsieh; Ni-Chung Lee
Journal:  Eur J Pediatr       Date:  2007-09-11       Impact factor: 3.183

Review 3.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

Review 4.  Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases.

Authors:  F Lamari; F Mochel; F Sedel; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  2012-07-20       Impact factor: 4.982

5.  Cardiolipin-induced activation of pyruvate dehydrogenase links mitochondrial lipid biosynthesis to TCA cycle function.

Authors:  Yiran Li; Wenjia Lou; Vaishnavi Raja; Simone Denis; Wenxi Yu; Michael W Schmidtke; Christian A Reynolds; Michael Schlame; Riekelt H Houtkooper; Miriam L Greenberg
Journal:  J Biol Chem       Date:  2019-06-11       Impact factor: 5.157

Review 6.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

7.  Neutropenia in Barth syndrome: characteristics, risks, and management.

Authors:  Colin G Steward; Sarah J Groves; Carolyn T Taylor; Melissa K Maisenbacher; Birgitta Versluys; Ruth A Newbury-Ecob; Hulya Ozsahin; Michaela K Damin; Valerie M Bowen; Katherine R McCurdy; Michael C Mackey; Audrey A Bolyard; David C Dale
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

8.  A Novel Exonic Splicing Mutation in the TAZ (G4.5) Gene in a Case with Atypical Barth Syndrome.

Authors:  Yuxin Fan; Jon Steller; Iris L Gonzalez; Wim Kulik; Michelle Fox; Richard Chang; Brandy A Westerfield; Anjan S Batra; Raymond Yu Jeang Wang; Natalie M Gallant; Liana S Pena; Hu Wang; Taosheng Huang; Sunita Bhuta; Daniel J Penny; Edward R McCabe; Virginia E Kimonis
Journal:  JIMD Rep       Date:  2013-04-19

9.  Diagnosis of Barth syndrome using a novel LC-MS/MS method for leukocyte cardiolipin analysis.

Authors:  Ann Bowron; Robert Frost; Vicki E C Powers; Paul H Thomas; Simon J R Heales; Colin G Steward
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

Review 10.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.